LIFERIVER(SH:688317)2021-10-28 16:00Financial Performance - The company's revenue for Q3 2021 was ¥573,540,299.36, representing a decrease of 4.34% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥215,960,907.48, down 19.33% year-on-year[5] - The basic earnings per share for Q3 2021 was ¥1.11, a decrease of 39.50% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥199,479,814.25, a decrease of 25.77% year-on-year[5] - Net profit for the third quarter of 2021 was ¥602,748,336.97, down from ¥695,539,406.89 in the same quarter of 2020, reflecting a decrease of approximately 13.3%[20] - The company reported a total comprehensive income of ¥572,393,149.79 for the third quarter of 2021, compared to ¥707,645,007.85 in the same quarter of 2020, indicating a decline of about 19.0%[21] Research and Development - Research and development expenses totaled ¥25,880,131.10 for Q3 2021, an increase of 187.71% year-on-year, accounting for 4.51% of revenue[6] - Research and development expenses for the first three quarters of 2021 were ¥58,658,299.41, significantly higher than ¥25,389,465.27 in 2020, representing an increase of about 130.9%[19] Assets and Equity - Total assets as of the end of Q3 2021 reached ¥4,086,799,124.44, a 117.43% increase from the end of the previous year[6] - The total equity attributable to shareholders at the end of Q3 2021 was ¥3,665,786,411.72, reflecting a 150.64% increase from the end of the previous year[9] - The company's total assets as of the end of the third quarter of 2021 amounted to ¥4,086,799,124.44, compared to ¥1,879,571,653.56 at the end of the same period in 2020, showing a significant increase of about 117.5%[19] - The company's equity attributable to shareholders reached ¥3,665,786,411.72, compared to ¥1,462,598,582.88 in the same period of 2020, marking an increase of approximately 150.5%[19] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥377,237,951.43, down 50.95% compared to the previous year[5] - The cash inflow from operating activities for the first three quarters of 2021 was CNY 1,518,159,879.48, an increase from CNY 1,416,223,487.96 in the same period of 2020, representing a growth of approximately 7.2%[22] - The net cash flow from operating activities decreased to CNY 377,237,951.43 in Q3 2021, down from CNY 769,124,283.43 in Q3 2020, indicating a decline of about 51%[23] - The total cash outflow from investing activities in Q3 2021 was CNY 500,888,576.14, significantly higher than CNY 75,113,809.10 in Q3 2020, reflecting an increase of approximately 570%[23] - The net cash flow from financing activities in Q3 2021 was CNY 1,634,636,679.05, compared to a negative cash flow of CNY 68,520,717.90 in Q3 2020, showing a substantial improvement[23] - The total cash and cash equivalents at the end of Q3 2021 reached CNY 2,712,942,397.63, up from CNY 861,152,810.40 at the end of Q3 2020, marking an increase of approximately 215%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,432[11] - The top ten shareholders hold a combined 33.3% of the shares, with Shanghai Zhijiang Pharmaceutical Co., Ltd. being the largest shareholder at 64,969,560 shares, or 33.3%[11] - The actual controller and chairman, Mr. Shao Junbin, plans to increase his shareholding by investing between ¥10 million and ¥15 million over a six-month period starting September 1, 2021, reflecting confidence in the company's future[14] Government Subsidies and Non-Recurring Gains - The company reported a total of ¥20,353,048.17 in government subsidies recognized in Q3 2021, contributing to non-recurring gains[7] Market and Product Development - The company has disclosed plans for market expansion and product development, focusing on enhancing its product portfolio and competitive edge[14] - The company received EU CE certification for several products, including COVID-19 testing kits and automated nucleic acid extraction instruments, enhancing its market competitiveness[14] Operating Costs - Total operating costs for the first three quarters of 2021 were ¥783,020,268, compared to ¥585,948,095 in 2020, indicating an increase of about 33.6%[19] Audit and Compliance - The company has not reported any audit opinion type applicable for the financial statements as of September 30, 2021[15] - The company did not apply the new leasing standards for the first time in 2021, which may impact future financial reporting[24] Related Party Relationships - The company has disclosed that it is unknown whether other shareholders have any related party relationships or concerted action relationships, aside from the known connections[12]